Posted by Michael Wonder on 08 May 2025
PHARMAC funds and widens access to melanoma medicines
9 May 2025 - PHARMAC is funding more medicines for people with skin cancer (melanoma), from 1 June 2025.
The decision includes widening access to pembrolizumab (Keytruda) and funding dabrafenib (Tafinlar) and trametinib (Mekinist) for the first time. They will be funded for people with stage 3B to stage 4 melanoma.
